36 results
8-K
EX-10.1
QLGN
Qualigen Therapeutics Inc
27 Feb 24
Entry into a Material Definitive Agreement
7:00am
of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its
8-K
EX-2.1
QLGN
Qualigen Therapeutics Inc
26 Jul 23
Entry into a Material Definitive Agreement
5:25pm
authorization, manufacturing facilities compliance, packaging, good manufacturing practices, labeling, advertising, promotional practices, safety
8-K
EX-10.1
n311fgrc
22 Dec 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.1
g0zfva ko
1 Dec 21
Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering
3:39pm
424B5
hab2tykm
1 Dec 21
Prospectus supplement for primary offering
2:28pm
10-KT
5cn5 t1wjw
31 Mar 21
Annual report (with FYE transition)
4:33pm
8-K
EX-10.1
4qyfwa
18 Dec 20
Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering
3:54pm
424B5
m8n0lpuye9pu0e
18 Dec 20
Prospectus supplement for primary offering
1:26pm
424B5
n2fqpwamaaym6iov0we
2 Oct 20
Prospectus supplement for primary offering
4:24pm
8-K
EX-10.1
aouicc8
4 Aug 20
Qualigen Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:25pm
424B5
c5c7w7pwqxuwvw
4 Aug 20
Prospectus supplement for primary offering
6:16am
8-K
EX-10.1
hufkeqp3cx95hfxrw
10 Jul 20
Qualigen Therapeutics, Inc. Announces Closing of $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:40pm
424B5
tlvxitbafsi7qagdm
10 Jul 20
Prospectus supplement for primary offering
2:35pm
8-K
EX-10.1
0qeklb4whqj1
9 Jul 20
Qualigen Therapeutics, Inc. Announces $8 Million
6:02am
8-K
EX-10.11
b74hpest sow5
29 May 20
Qualigen Therapeutics Announces Merger Closing
5:03pm